Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Total Current Liabilities (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Total Current Liabilities for 4 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 67.72% to $2.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a 67.72% increase, with the full-year FY2024 number at $1.7 million, down 41.55% from a year prior.
  • Total Current Liabilities was $2.2 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $1.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $28.9 million in Q2 2023 to a low of $1.1 million in Q1 2024.
  • A 4-year average of $6.3 million and a median of $1.8 million in 2025 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: tumbled 95.78% in 2024, then surged 67.72% in 2025.
  • 60 Degrees Pharmaceuticals' Total Current Liabilities stood at $23.9 million in 2022, then tumbled by 88.15% to $2.8 million in 2023, then crashed by 41.55% to $1.7 million in 2024, then soared by 32.6% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Total Current Liabilities are $2.2 million (Q3 2025), $1.7 million (Q2 2025), and $1.8 million (Q1 2025).